newsfilter
← Latest News
GlobeNewswire·

Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®

Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trialUpdated deep B cell depletion and clinical response data is consistent with previously reported findings; however,